Otten H G, Joosten I, Allebes W A, van der Meer A, Hilbrands L B, Baas M, Spierings E, Hack C E, van Reekum F, van Zuilen A D, Verhaar M C, Bots M L, Seelen M A J, Sanders J S F, Hepkema B G, Lambeck A J, Bungener L B, Roozendaal C, Tilanus M G J, Vanderlocht J, Voorter C E, Wieten L, van Duijnhoven E, Gelens M, Christiaans M, van Ittersum F, Nurmohamed A, Lardy N M, Swelsen W T, van Donselaar-van der Pant K A M I, van der Weerd N C, Ten Berge I J M, Bemelman F J, Hoitsma A J, de Fijter J W, Betjes M G H, Roelen D L, Claas F H J
UMC Utrecht, Laboratory for Translational Immunology, The Netherlands.
Radboudumc, Dept. of Laboratory Medicine, The Netherlands.
Transpl Immunol. 2014 Oct;31(4):184-90. doi: 10.1016/j.trim.2014.09.008. Epub 2014 Oct 1.
Kidney transplantation is the best treatment option for patients with end-stage renal failure. At present, approximately 800 Dutch patients are registered on the active waiting list of Eurotransplant. The waiting time in the Netherlands for a kidney from a deceased donor is on average between 3 and 4 years. During this period, patients are fully dependent on dialysis, which replaces only partly the renal function, whereas the quality of life is limited. Mortality among patients on the waiting list is high. In order to increase the number of kidney donors, several initiatives have been undertaken by the Dutch Kidney Foundation including national calls for donor registration and providing information on organ donation and kidney transplantation. The aim of the national PROCARE consortium is to develop improved matching algorithms that will lead to a prolonged survival of transplanted donor kidneys and a reduced HLA immunization. The latter will positively affect the waiting time for a retransplantation. The present algorithm for allocation is among others based on matching for HLA antigens, which were originally defined by antibodies using serological typing techniques. However, several studies suggest that this algorithm needs adaptation and that other immune parameters which are currently not included may assist in improving graft survival rates. We will employ a multicenter-based evaluation on 5429 patients transplanted between 1995 and 2005 in the Netherlands. The association between key clinical endpoints and selected laboratory defined parameters will be examined, including Luminex-defined HLA antibody specificities, T and B cell epitopes recognized on the mismatched HLA antigens, non-HLA antibodies, and also polymorphisms in complement and Fc receptors functionally associated with effector functions of anti-graft antibodies. From these data, key parameters determining the success of kidney transplantation will be identified which will lead to the identification of additional parameters to be included in future matching algorithms aiming to extend survival of transplanted kidneys and to diminish HLA immunization. Computer simulation studies will reveal the number of patients having a direct benefit from improved matching, the effect on shortening of the waiting list, and the decrease in waiting time.
肾移植是终末期肾衰竭患者的最佳治疗选择。目前,约800名荷兰患者在欧洲移植协会的活跃等待名单上登记。在荷兰,等待已故捐赠者肾脏的时间平均为3至4年。在此期间,患者完全依赖透析,而透析仅部分替代肾功能,生活质量受限。等待名单上的患者死亡率很高。为了增加肾脏捐赠者数量,荷兰肾脏基金会采取了多项举措,包括全国性的捐赠者登记呼吁以及提供器官捐赠和肾移植信息。全国性的PROCARE联盟的目标是开发改进的匹配算法,以延长移植的捐赠肾脏的存活时间并减少HLA免疫。后者将对再次移植的等待时间产生积极影响。目前的分配算法除其他外基于HLA抗原匹配,这些抗原最初是通过血清学分型技术由抗体定义的。然而,多项研究表明该算法需要调整,目前未纳入的其他免疫参数可能有助于提高移植物存活率。我们将对1995年至2005年在荷兰接受移植的5429名患者进行多中心评估。将检查关键临床终点与选定的实验室定义参数之间的关联,包括Luminex定义的HLA抗体特异性、在不匹配的HLA抗原上识别的T和B细胞表位、非HLA抗体,以及与抗移植抗体的效应功能在功能上相关的补体和Fc受体中的多态性。从这些数据中,将确定决定肾移植成功的关键参数,这将导致识别出未来匹配算法中要纳入的其他参数,旨在延长移植肾脏的存活时间并减少HLA免疫。计算机模拟研究将揭示因改进匹配而直接受益的患者数量、对缩短等待名单的影响以及等待时间的减少。